KHK-IN-1

®

MedChemExpress

Cat. No.:	HY-12841	
CAS No.:	1303469-70-6	S H N N
Molecular Formula:	$C_{21}H_{26}N_8S$	
Molecular Weight:	422.55	Ň Ň
Target:	Ketohexokinase	∠ ^N ∖
Pathway:	Metabolic Enzyme/Protease	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	Ĥ

 \bigtriangledown

Product Data Sheet

Description	KHK-IN-1 (compound 8) is a selective and cell membrane permeable ketohexokinase (KHK) inhibitor (IC ₅₀ =12 nM; F=34%). KHK-IN-1 inhibits the production of F1P in HepG2 cell lysates (IC>sub>50=400 nM). KHK-IN-1 has potential for the study of diabetes and obesity ^[1] .		
IC ₅₀ & Target	IC50=12 nM (KHK) ^[1] .		
In Vitro	KHK-IN-1 stable in human and rat liver microsome preparations (88 and 72% remaining at 10 min) and do not significantly inhibit cytochrome P450s from human liver microsomes (1A2, 2C19, 2D6, 2C9, and 3A4) ^[1] . KHK-IN-1 (0-10 μM; incubate 30 min, then add to 15 mM fructose and incubate for another 3 h) inhibits production of F1P in HepG2 cell lysates with an IC ₅₀ value of 400 nM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1]		
	Cell Line:	HepG2 cells	
	Concentration:	0-10 μΜ	
	Incubation Time:	Incubate 30 min, then add to 15 mM fructose and incubate for another 3 h	
	Result:	Exhibited inhibition of F1P production in HepG2 cell lysates (IC ₅₀ =400 nM).	
In Vivo	KHK-IN-1 (10 mg/kg; p.o.; single) shows oral bioavailability of 34% in rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Male Sprague-Dawley rats (~250 g) ^[1] .	
	Dosage:	10 mg/kg	
	Administration:	Oral gavage; single	
	Result:	Exhibited reasonable oral bioavailability in rats (F=34%; oral $t_{1/2}$ =4 h), but had a high volume of distribution (Vd _{ss} = 32 L/kg) and a high rate of clearance (CL=160 mL/min/kg).	

REFERENCES

[1]. Maryanoff BE, et al. Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site. ACS Med Chem Lett. 2011 Apr 18;2(7):538-43.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA